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Protocol
AbstrACt
Introduction Patients can develop trismus from their 
head and neck cancer or as a result of treatment. Trismus 
affects the jaw muscles and makes mouth opening 
difficult. To potentially combat trismus, patients could 
undertake proactive jaw stretching exercises prior to, 
during and after radiotherapy, although currently these are 
not the standard of care.
Methods and analysis This is a randomised, open-
label, controlled, two-centre feasibility study, to assess 
the objective and subjective effectiveness and cost-
effectiveness of therabite use compared with wooden 
spatula in ameliorating trismus in patients treated 
for stage 3 and 4 oral and oropharyngeal cancer, 
managed either by primary surgery followed by (chemo)
radiotherapy or primary (chemo)radiotherapy. The 
principal objective assessment is measurement of 
maximum jaw opening. Assessments in all cases will 
be performed preradiotherapy and again at 3 and 6 
months postintervention. Secondary aims of the study 
will be (1) to assess whether therabite or the wooden 
spatula intervention improves patients’ quality of life, (2) 
reduce the level of post-treatment clinical management/
healthcare use and (3) a nested qualitative study will 
explore the experience of the patient taking part in the 
intervention; data will be transcribed verbatim and analysis 
will be based on content analysis methods using the 
interview questions as the framework for examination.
Ethics and dissemination North West Greater 
Manchester granted ethical approval (REC Reference 11/
NW/0744). Good Clinical Practice and the Declaration 
of Helsinki have been adhered to. The results will be 
presented internationally and submitted to a peer-reviewed 
journal. Head and neck cancer charities and information 
websites will also be approached.
trial registration number NCT01733797.
IntroduCtIon
Patients with head and neck cancer can expe-
rience a variety of complications following 
surgery and/or radiation/chemoradiation, 
including limited mouth opening or trismus.1 
Trismus will affect the ability to chew food, 
speak coherently, brush completely the 
lingual or palatal surfaces of the teeth, have 
routine dental assessment and oral examina-
tion to detect possible cancer recurrence. 
This can lead to malnutrition and lack of 
energy, chronic periodontal disease, caries, 
dental integrity with risk of osteoradione-
crosis of the jaw.2–5 These patients may also 
suffer from lack of intimacy due to lack of 
kissing function, lack of self- esteem, depres-
sion, suicide tendencies and altered body 
image with nearly 60% of patients feeling 
discounted or stigmatised because of their 
cancer-related appearance.6 7 
Only a few studies exist in which the effects 
of interventions on trismus have been investi-
gated. Buchbinder conducted a randomised 
clinical trial (RCT) with 21 patients who had 
radiation-induced trismus. At the end of the 
10-week period, the group of patients using 
the therabite system (n=7) had shown the 
greatest improvement (mean of 13 mm), 
while the group using tongue depressors 
(n=7) only showed a modest improvement 
strengths and limitations of the study
 ► Adequately powered, multicentre, randomised con-
trolled trial aiming to establish whether it is feasi-
ble and acceptable to perform proactive exercises 
throughout and beyond a course of radiotherapy.
 ► Health economics input to assess the level of 
post-treatment clinical management/healthcare use 
required by patients with mouth cancer.
 ► Study also includes a nested qualitative component 
to gain insight from patients’ perspective.
 ► A small-scale study of patient acceptability of the 
intervention during radiotherapy would have been 
beneficial prior to study commencement.
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of less than 5 mm on average.8 Maloney conducted a 
RCT with 46 patients with temporomandibular joint 
(TMJ) disease comparing the use of therabite and an 
intraoral appliance (n=17), the use of tongue depressors 
in combination with an intraoral appliance (n=12) and an 
intraoral appliance only (n=17). It showed that patients 
using the therabite experienced increased mobility and 
decreased pain compared with the group using intraoral 
appliance alone.9 Cohen studied the use of therabite in 
the early postoperative management of trismus in only 
seven patients who had surgical treatment and recon-
struction for head and neck cancer. The authors report 
that the use of therabite increased the range of motion 
and decreased pain in both muscle and joint disorders.10 
Finally, a systematic review carried out by McNeely et al on 
the effectiveness of physical interventions for TMJ disor-
ders concluded that the results support the use of active 
and passive oral exercises as effective interventions to 
reduce trismus.11 This handful of studies shows that the 
use of therabite after radiotherapy and/or surgical treat-
ments can improve maximum mouth opening, but some 
publications had not used a control group with which to 
compare maximum mouth opening readings. Also, all 
studies had small sample sizes and power calculations 
were not reported.
MEthods And AnAlysIs
design
This is a randomised, controlled two-centre pilot study, 
to assess the feasibility of therabite use compared with 
wooden spatula in ameliorating trismus in patients 
treated for stages 3 and 4 oral and oropharyngeal cancer.
settings
Christie Hospital National Health Sevice (NHS) Trust 
(with MRI/Wythenshawe/Pennine NHS Trust hospitals) 
and Aintree Hospital NHS Trust.
sample
The cohort will comprise previously untreated patients 
with stage 3 and 4 oral and oropharyngeal cancer 
managed either by chemoradiotherapy or surgery 
followed by (chemo)radiotherapy. Disruption of the TMJ, 
the pterygoid muscles or the masseter muscle is likely to 
result in trismus, and hence patients having surgery or 
radiotherapy in the vicinity of these joints/muscles will 
form the sample of this study.
The inclusion of patients in stages 3 and 4 comes from 
the evidence that T3/4 patients are most likely to develop 
trismus.12 The use of the therabite may prevent deterio-
ration by maintaining or improving range of movement.
Inclusion/Exclusion criteria
Inclusion
 ► Provision of signed, written informed consent.
 ► Aged 18 years and older.
 ► Able to read and write English sufficiently to be able 
to complete the validated questionnaires.
 ► Stage 3/4 oral and oropharyngeal cancer patients 
undergoing:
primary chemoradiotherapy or postoperative radio-
therapy or postoperative chemoradiotherapy.
 ► All patients will receive 60–70 Gy in 30–35 fractions 
over 6 to 7 weeks to the region of the masticatory 
muscles.
Exclusion
 ► <12 mm mouth opening (cannot use therabite).
 ► Anatomically unable to use therabite for example 
patients who may only be partially dentate and to 
use the therabite would place extreme stress on the 
existing teeth).
 ► Cognitive impairment as judged by the clinicians.
 ► Some patients with mouth cancer present at an 
advanced stage, and the treating consultant will use 
clinical judgement as to their inclusion or exclusion 
to the study.
 ► All patients who the treating consultant deems too 
unwell to use the therabite instrument will also be 
excluded. This may also include patients whose 
alcohol dependency may result in their non-compli-
ance with future assessments.
 ► International patients treated at The Christie or 
Aintree Hospital who may not have routine follow-up 
at these sites.
Intervention
The Therabite Jaw Motion Rehabilitations System (Platon 
Medical) will be used.13 This is a patient-controlled jaw 
mobilisation device which employs anatomically correct, 
repetitive passive motion and stretching to help restore 
proper jaw opening. The suggested improvement in jaw 
function comes about via a combination of stretching of 
connective tissues, mobilisation of joints and strength-
ening muscles across their full range of motion. Patients 
will be trained on the safe use of therabite or wooden 
spatula and recording procedure prior to commence-
ment of primary chemoradiotherapy or after primary 
surgery. This at their prechemoradiotherapy assessment 
day, whichever visit is more convenient for the patient.
No known adverse effects have been documented or 
reported from patients using the therabite. General and 
user information for the therabite will be given with the 
device to patients.
therabite protocol
For patients randomised to therabite use, they will be 
asked to follow the 5-5-30 protocol which is:
 ► Five sessions per day.
 ► Five openings/closing per session.
 ► 30 s stretch for each opening.
This regime has been selected after consultation 
with Platon medical who manufacture the equipment 
and has worldwide experience of using the device. The 
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importance of motion in the rehabilitation of patients 
with mandibular hypomobility is also supported by the 
literature. Israel and Syrop’s review highlights the point 
that the TMJ is a synovial joint and as such functions as 
the same as other synovial joints in the body. Therefore, 
lack of mobility of the TMJ may lead to restrictions in 
maximum mouth opening fairly rapidly.14
Patients will commence therabite use approximately 
3/4 weeks postsurgery. Based on the literature, it is imper-
ative that therabite use is encouraged as early as possible 
and maintained to achieve maximum benefit for patients 
with mandibular hypomobility.15 This is further supported 
by Melchers who performed a qualitative study of positive 
and negative aspects influencing adherence when using 
the therabite device, reporting that goal setting, belief 
and self-discipline were all positive factors.16
Control group: wooden spatula
Wooden tongue depressors or ‘spatulas’ have been demon-
strated to be ineffective in the management of established 
trismus in patients with head and neck cancer,8 although 
at present form the basis for best supportive care for the 
management of trismus. This treatment is also a passive 
form of exercise designed to increase mouth opening 
range. Standard wooden tongue depressors will be used, 
measuring approximately 1.25 mm in thickness and 
14 mm in width.
The use of the wooden tongue depressors will 
commence at randomisation and patients will be asked to 
complete the 5-5-30 regime. Patients will be instructed to 
place a maximum number of wooden spatulas in between 
their front teeth.
An additional spatula will be placed in between the 
already stacked spatulas. The number of spatulas placed 
for each treatment will be recorded by the patient.
Assessment scales
Postsurgical maximum mouth opening and health-re-
lated quality of life (HRQoL) assessments will take place 
at 3 to 4 weeks. This is the optimal time prior to the start 
of radiotherapy treatment. Follow-up assessments will 
take place at 3 and 6 months following start of interven-
tion. More specifically, patients will undergo the following 
assessments.
Primary outcome
 Maximum mouth opening using the Willis Gauge 
(primary outcome).
Secondary outcomes
Interincisor maximal mouth opening measured using the therabite 
motion scale
Mouth opening measurements will be recorded using 
the Willis Bite Gauge (SS White Group, Gloucester, UK) 
and measured in millimetres (mm) for both dentate 
and edentulous patients. These measurements are taken 
from the top of the philtrum to the under surface of the 
mandible.
A chart will be used to record which teeth were used 
to record the measurements using the Therabite Motion 
Scale. This is so that subsequent recordings will use the 
same landmarks for each individual patient.
HRQoL
QoL will be assessed using the European Organisation 
for Research and Treatment of Cancer Quality of Life 
Questionnaire (EORTC QLQ-C 30) and head and neck 
(H&N) module (EORTC QLQ H&N 35). These question-
naires have been validated and have been shown to be 
reliable in detecting QoL changes in patients with H&N 
cancer17–20 Data will be collected using a touchscreen 
data collection method. Patients will be encouraged to 
complete questionnaires on their own to help reduce 
bias.
Use of secondary health services
Costs will be identified, measured and valued using a 
microcosting approach, by which each component of 
resource use is identified, estimated and a unit cost derived 
from market prices and national estimates. The cost anal-
ysis will be performed from the perspective of the health 
service provider and from a societal perspective. Included 
in the healthcare provider costs will be those accrued by 
the acute trusts. Costs to the patients and their families, 
including social care, will be considered as the additional 
costs for society. It will be in the form of a structured inter-
view documenting which healthcare professionals the 
patients have visited. Structured interview will take place 
at the 3 months and 6 months postintervention, covering 
the previous 3 months. Patients will also be asked which 
secondary healthcare services they have been referred to. 
Such services may include speech and language therapy, 
dietary and nutritional advice and/or artificial feeding 
and orthodontic interventions including surgery. Patient 
notes will be also be audited; however, as records may not 
always be complete, patient interviews are deemed to be a 
more accurate assessment of use of healthcare resources. 
Study patients will be monitored and any clinical inter-
ventions recorded. An estimate of costs of interventions 
will be made, an average cost per patient calculated, and 
this will be compared between study and control patients. 
The aim of this is to assess whether the potential economic 
benefit of therabite offsets its cost of £250 per patient.
Patient characteristics will include age, gender, treat-
ment, dentate, site of cancer, stage of tumour, alcohol 
use and radiotherapy dose and will be obtained from the 
medical records.
Nested qualitative study
All patients will be approached by the medical team at the 
6-month time schedule to be included in the nested qual-
itative study. Telephone interviews will be conducted with 
patients in their own home by the researcher RL within 
3 months of completing the exercise regime and will 
explore the experience of the patient taking part in the 
intervention, any issues that participants found difficult 
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during the intervention, any problems with the therabite 
or wooden spatula and the mouth exercises, issues around 
compliance with the protocol or interference of the inter-
vention with their lives and whether pain has been an 
issue in their compliance with the intervention. Hence, 
these interviews will aim to explore any practical issues 
that make the delivery of the intervention less feasible  to 
control or consider such variables in a future phase III 
trial. A blank copy of interview schedule is available. Data 
will be tape-recorded and transcribed verbatim; data anal-
ysis will be performed by RL and researchers with exper-
tise in qualitative methods, based on content analysis 
methods using the interview questions as the framework 
of analysis by Richie and Spencer.21 Field notes will be 
taken during the interview, and all data coding and emer-
gent themes will be provided as well as participant quota-
tions to illustrate the findings and divergent themes in a 
transparent and reproducible manner. The Consolidated 
Criteria for Reporting Qualitative Research checklist will 
be used to report important aspects of the research team, 
reflexivity of the researchers, study design, data analysis 
and reporting.
sample size
Since we are measuring the difference within each patient 
from their baseline to 6 months postintervention, we are 
not going to adjust for gender or dentate state (each 
person acts as their own control). This pilot will give us 
information on whether we need to adjust for these in a 
future phase III study. From published literature, we esti-
mated that the SD of the differences in each of the treat-
ment groups could be as high as 10 mm being the worse 
case scenario.
In our prevalence study,22 median mouth opening was 
40 mm when the patient could chew as well as ever, 30 mm 
when soft solids could be eaten but some foods could not 
be chewed and 24 mm when even soft solids could not be 
chewed. We estimate that if we want to detect a minimum 
of 5 mm improvement from the background difference, 
which is our control arm (no intervention), the common 
SD is 8 mm (patients that have had no intervention and 
have had radiotherapy). Based on our prevalence study 
data, if we wish to detect a difference between the two 
arms of 5 mm change with an SD of 8 mm with 80% power, 
we would require 42 cases per group. With an additional 
25% attrition rate (as we have seen in our prevalence 
study), 112 patients will be required.
recruitment rate
The planned recruitment rate will be two patients 
per week across the two centres at Liverpool and 
Manchester (catchment population is approximately 
5 million). On average, Christie and Aintree Hospital will 
see 1000 patients with head and neck cancer a year. Of 
these, approximately half will be oral and oropharyngeal 
patients. Of these 500 patients, 60% will be stage 3 and 4, 
giving a potential pool of 300 patients. Of these, 100 may 
not be suitable on account of clinical factors.
The following factors may affect compliance (with both 
regimes):
 ► Pain.
 ► Anxiety.
 ► Radiation induced mucositis.
 ► Alcohol dependency.
A recent study by Melchers et al indicated that pain 
due to radiation-induced mucositis had a negative effect 
on adherence when using the therabite device. Other 
factors such as anxiety, ill-fitting therabite pads and the 
lack of goal setting during treatment also had a nega-
tive effect.16 It is our intention therefore to monitor for 
these symptoms/problems during the patients’ course of 
treatment and manage accordingly. However, there have 
been reports that patients with higher initial pain and jaw 
use limitation levels were more compliant with treatment 
recommendations.9
Patients who are alcohol dependent prior to randomi-
sation may be excluded following clinical assessment by 
both the patients’ consultant and the researchers.
randomisation
Randomisation will be by the minimisation method. Allo-
cation will be equal between the two arms of the trial 
and will be administered centrally by the Manchester 
Academic Health Sciences Centre Trials Co-ordination 
Unit (MAHSC-CTU). There will be no replacement of 
patients who fail for whatever reason to take part in the 
trial.
Patient identification (ID) will be by trial ID which will 
be a sequential number from 001 to the total number of 
patients in the trial. Any patient who fulfils the criteria for 
inclusion and takes part will be evaluable, unless there 
is a serious deviation from the protocol. For example, 
patients who do not receive radiotherapy or who do o’t 
have measurements of mouth opening at 3 and 6 months 
would not be evaluable, though they would remain in the 
study.
Analyses plan
Descriptive statistics will be used to identify prevalence of 
trismus between the two groups and mouth openings. Simi-
larly, descriptive statistics will be calculated for number of 
patients completing the study and amount of data missing 
from the questionnaires. The analysis would further 
involve a two-tailed unpaired t-test at the 5% significance 
level. The change from baseline to 6 months for each case 
would be compared between treatment group 1 and treat-
ment group 2. Power calculations will take place to assess 
the number of patients required for a phase III trial.
The effect of missing values will be assessed by comparing 
the numbers and percentages of participants with missing 
values in the two arms of the study; differences in baseline 
variables between participants with observed and missing 
outcomes in each arm and for participants with observed 
outcomes, differences in baseline variables between the 
two arms. Logistic regression models will be used to assess 
potential factors affecting dropout.
group.bmj.com on April 8, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
5Lee R, et al. BMJ Open 2018;8:e021938. doi:10.1136/bmjopen-2018-021938
Open Access
Analysis of economic data: the total cost of each arm of 
the trial will be calculated by combining the resource use 
and unit cost data. No discounting is necessary given the 
time period of data collection (less than 1 year); sensitivity 
analysis will be carried out to account for uncertainty 
where estimates in cost data are used. Differences in costs 
between the two arms will be tested for using indepen-
dent sample t-tests. Analysis will be carried out by a health 
economist.
hrQol
QOL will be assessed using the EORTC QLQ-C 30 and 
H&N module (EORTC QLQ H&N 35). These question-
naires have been validated and have been shown to be 
reliable in detecting QOL changes in patients with H&N 
cancer17–20 Patients will be encouraged to complete ques-
tionnaires on their own to help reduce bias. It is expected 
that some of the QOL subscales will be more sensitive 
to change than others (these are likely to be subscales 
around ‘eating’, ‘weight loss’, ‘pain’, ‘taste’, ‘chewing’ 
as we have seen in our recently completed longitudinal 
observational study22 and will establish the appropriate 
scales to be used in the phase III trial but also required 
sample sizes.
health economics assessments
EQ-5D questionnaire. This is a validated generic, 
health-related, preference-based measure comprising 
five domains: mobility; self-care; usual activities; pain and 
discomfort; anxiety and depression. Each domain has 
three levels (no problems, some problems and a lot of 
problems). The questions are complemented by a visual 
analogue scale on which respondents are asked to indi-
cate their current health.23 24
ICEpop CAPability measure for adults (ICECAP-A). 
This is a more encompassing quality of life measure. 
There are five domains’: attachment, security, role, enjoy-
ment and independence. There are four levels of capa-
bility ranging from a lot to none.
Measurement of costs for health economics analysis
Overall economic question for the planned full RCT
What is the incremental cost-effectiveness of therabite in 
the management of trismus in patients with H&N cancer 
as compared with treatment as usual?
Feasibility study questions
We will explore how well generic HRQoL measures, that 
is, EQ-5D and ICECAP-A perform in this patient group—
for the purpose of quality-adjusted life year (QALY) calcu-
lation in the planned full RCT.
We will explore the sensitivity of these measures, 
comparing patient responses with cancer-specific HRQoL 
measures in this feasibility study.
We will explore the extent to which an interview-based 
client service receipt inventory (CSRI) can capture 
frequency and type of service contracts based on patient 
recall over 3 months.
For this patient group, we will be particularly interested 
in asking patients about their contacts with such services 
as speech and language therapy, dietary and nutritional 
advice and/or artificial feeding and orthodontic inter-
ventions including surgery. Patient notes will be also be 
audited, as records may not always be complete. Patient 
interviews are deemed to be a more accurate assessment 
of use of healthcare resources in this patient group.
Preliminary incremental cost-effectiveness ratio calcu-
lation to explore power issues in an economic analysis 
alongside the planned full RCT.
From an NHS perspective, the following health 
economic analysis will be performed:
1. Undertake a microcosting of the therabite 
intervention.
2. Record study participant primary and secondary care 
health service use, social care and voluntary sector use 
(using an interviewer administered CSRI, costed us-
ing national unit costs.
3. Explore whether it is feasible for the main planned 
full RCT to adopt a cost-utility approach, calculating 
cost per QALY, which has more meaning for patient 
QoL than for example, cost-effectiveness analysis us-
ing the Willis gauge as a measure of maximum mouth 
opening.
4. Using pilot data from the feasibility study, we will 
explore how bootstrapping enables us to generate 
cost-effectiveness acceptability curves to communicate 
to policy-makers the probability that the therabite in-
tervention is cost-effective.
5. Suggest appropriate sensitivity analysis and subgroup 
analysis strategies to explore uncertainties in the 
planned full RCT.
data analysis
Descriptive statistics will be used to identify prevalence 
of trismus between the two groups and mouth open-
ings. Similarly, descriptive statistics will be calculated for 
number of patients completing the study and amount of 
data missing. The primary analysis would further involve a 
two-tailed unpaired t-test at the 5% significance level. The 
change from baseline to 6 months for each case would 
be compared between treatment group 1 and treatment 
group 2. Power calculations will take place to assess the 
number of patients required for a phase III trial.
The secondary analysis will be an analysis of compliance. 
This will be a normal distribution test of the proportion 
of the log completed by each patient, taking into account 
that some patients might not complete the full 6 months 
of the log.
Probable/possible outputs
This is a feasibility trial progressing to a phase III trial; 
if results are positive in the phase III trial, our interven-
tion can be recommended for use in the NHS. The need 
for lengthy and expensive operations to try and correct 
trismus can also be reduced and patients may see improve-
ments in all aspects of quality of life. We anticipate that 
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this research will lead to alleviation of symptoms including 
restriction/pain with mouth opening, inability to eat in 
front of friends/family or in public, poor oral hygiene or 
inability to have dentures fitted. Restrictions in mouth 
opening will also hamper access for clinical assessment 
of local recurrence. This evidence base may also benefit 
the wider NHS by reducing the levels of post-treatment 
clinical, dental and psychological management required 
by these patients.
Primary and secondary analysis
Analysis will be done by commercially available statistical 
software, SPSS V.16 or S plus. The key variables in the 
primary and secondary analyses will be presented using 
the appropriate tables which show means, SD and CIs.
The null hypothesis for the primary analysis will be that 
there is no difference in the amount of mouth opening 
at 6 months between the two arms of the trial. The alter-
native will be two sided: it is unspecified which arm will 
result in more or less mouth opening.
The null hypothesis for the secondary analysis will be 
that there is no difference between the two arms in the 
proportion of the log completed by each patient. As 
before the alternative will be two sided: it is unspecified 
which arm will result in a higher proportion of the log 
each patient has to complete.
Patients who withdraw or do not receive any assessment 
of mouth opening after they enter the trial will be missing 
with regards to the primary analysis. With regard to the 
secondary analysis, if patients do not enter any data into 
the log but are assessed after they enter the trial then the 
proportion completed will be zero.
EthICs And dIssEMInAtIon
The trial was approved by the Research Ethics Committee 
and each participating site R&D department prior to 
study start-up at the site. Great care will be taken to fully 
explain the study to the patients before fully informed 
consent is taken.
Sponsorship and clinical governance will be the respon-
sibility of The Christie NHS Foundation Trust Research 
and Development Division. The trial will be conducted in 
accordance with the principles of good clinical practice.
trial monitoring and oversight
The Clinical Trials Unit of The Christie will be respon-
sible for scientific, financial and administrative manage-
ment of the project in association with relevant trust 
departments.
The research team consisting of six members will form 
the basis of the trial management group and will meet 
formally every 2 months to assess progress of the project 
against agreed milestones, present results and address 
any delays or problems. An independent monitoring 
committee will not be formed as there is no drug involve-
ment and no risk to patients entering this study. The trial 
will be monitored by the Christie Trials Coordination 
Unit on the basis of a trial risk assessment.
Criteria for discontinuation
 ► Voluntary discontinuation by the patient.
 ► Severe non-compliance to the protocol as judged by 
the investigators.
 ► Patients lost to follow-up.
 ► Recurrence of tumour.
 ► Intercurrent illness.
 ► Withdrawal of consent to radiotherapy treatment or 
death of the patient.
 ► Participants are to be replaced to account for discon-
tinuation/withdrawal of participants while the study is 
still open to recruitment.
 ► The follow-up for withdrawn subjects will take place 
as standard, lead by the consultant supervising their 
radiotherapy treatment.
If discontinuation or withdrawal of participants takes 
place, then The Christie Clinical Trials Unit (CTU) will 
be informed.
All patients' will only complete the procedures if they 
are able to. If they are unable to continue to participate 
in the study then their data will be collected up to that 
point. If the patient is physically too weak to continue 
with the therabite or the tongue depressors, then data 
will be collected up to that point and included in the 
analysis. These data will be retained by the CTU for audit 
purposes. Patients may still be asked to complete the vali-
dated questionnaires if they are able.
A sentence will be included in the patient information 
sheet to inform them that all data from the maximum 
mouth opening and completed questionnaires will still be 
used.
Expected toxicity
None has been reported in the literature of either 
intervention.
serious adverse events
All serious adverse events occurring during radiotherapy 
will be faxed to the MAHSC-CTU, with the following 
exceptions:
 ► Serious adverse events (SAEs) representing an 
expected change or progression of the neoplastic 
condition that was the cause of treatment.
 ► Any grade of acute radiation toxicity (mentioned 
above) not requiring inpatient hospitalisation for 
specific treatment.
 ► Hospitalisation due to mucositis.
 ► Standard chemotherapy toxicities.
SAEs will be collected until 6 months after intervention 
which will be end of study.
Compliance issues and loss to follow-up
Melchers indicated that pain due to radiation-induced 
mucositis had a negative effect on adherence when using 
the therabite device. Other factors such as anxiety, ill-fit-
ting therabite pads and the lack of goal setting during 
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treatment also had a negative effect.16 Our intention is 
to monitor for these symptoms/problems during the 
patients’ course of treatment and manage accordingly. 
Compliance of each intervention will be monitored using 
a patient log book and allow us to calculate the compli-
ance rate. Such a log book has been used in a previous 
trial from our team based at The Christie, examining the 
tolerability of Manuka honey for oral mucositis. Compli-
ance will be enhanced by identifying key factors and 
addressing them during the study (ie, setting up with 
patients a clear goal from the exercise, addressing oral 
pain more effectively to allow exercises to take place, 
provide patients with reminders particularly as the time 
from enrolment increases).
In other studies of non-pharmacological interventions, 
we have carried out with this population, attrition from 
all reasons has been around 25% including death and 
recurrence within the 6 months follow-up.
trial closure
 ► After recruiting the desired number of patients 
into the study, the study will stop recruiting further 
patients.
 ► When all the recruited patients have completed their 
6 months of jaw exercises and the necessary data has 
been collected, the study will close.
 ► There is no planned follow-up period for the 
participants.
dissemination
The Macmillan Cancer Relief organisation will be 
approached to enhance patient dissemination. In keeping 
with previous clinical research by the authors, we intend 
to present at national and international meetings, such 
as the British Association of Head and Neck Oncologists, 
International Association of Oral and Maxillofacial Surgery 
and Quality of Life conferences in Head and Neck Cancer. 
Efforts will be made to update web-based information sites 
with the outcomes of our study including www. mouthca 
ncer foun dati on. org and www. headandneckcancer. co. uk/ 
Hospitals. All these efforts are aimed at giving patients with 
head and neck cancer with this debilitating condition, some 
hope that a scientifically robust study is aimed at helping 
them improve their overall quality of life.
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